LPH-5 shows not only selectivity for the serotonine 2A receptor over an extensive range of other pharmacological targets but has very low activity at the off-target homolog: the Serotonin 2B receptor, which is implicated in heart valve disease. LPH-5 has shown high potency at the Serotonin 2A receptor and has demonstrated in vivo target engagement and persistent anti-depressant effects in rodents following a single administration

LPH-5 meets the promise of the next generation of psychedelics. As a true NCE, LPH-5 is neither a prodrug nor a close analog of any known psychedelic. Inspired by scientific research into the phenethylamine compound class, LPH-5 is an improvement over the classic psychedelics, synthetically designed to remove problematic characteristics of the known compound classes.

LPH-5 boasts exceptional drugability characteristics including pharmacokinetics, non-promiscuous pharmacology, negligible Serotonin 2B receptor activation and is devoid of cytotoxicity or genotoxicity.